<p>Immunofluorescence staining of 4T1 (A-C) and MDA-MB-231 (D-E) tissues with 4T1pep1 and 4T1pep2. (A1-A3) 4T1 tissue section incubated with wild-type M13 phage (negative control). (B1-B3) 4T1 tissue section incubated with M13 phage displaying 4T1pep1, stained with DAPI (B1) and FITC (B2). (C1-C3) 4T1 tissue section incubated with M13 phage displaying 4T1pep2, stained with DAPI (C1) and FITC (C2). (D1-D3) MDA-MB-231 tissue section incubated with wild-type M13 phage (negative control). (E1-E3) MDA-MB-231 tissue section incubated with M13 phage displaying 4T1pep1, stained with DAPI (E1) and FITC (E2). (F1-F3) MDA-MB-231 tissue section incubated with M13 phage displaying 4T1pep2, stained with DAPI (F1) and FITC (F2).</p
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with poor prognosis and ...
To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I...
The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells i...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
[Excerpt] Breast cancer is the most frequent cancer amongst women, representing 25% of all cancer ca...
About 2.1 million new diagnosed breast cancer cases among women were estimated for 2018. Triple nega...
Abstract Background The F11R/JAM-A cell adhesion protein was examined as the therapeutic target in t...
<p><b>a</b>, A phage-display random peptide library was used to identify peptides that bind to the b...
To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I...
Background: Claudin-low breast carcinoma represents 19% of all breast cancer cases and is characteri...
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the lack of expres...
Triple-negative breast cancer (TNBC) is the most aggressive and difficult to treat subtype of breast...
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with poor prognosis and ...
To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I...
The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells i...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
The use of bacteriophages to select novel ligands has been widely explored for cancer therapy. Their...
[Excerpt] Breast cancer is the most frequent cancer amongst women, representing 25% of all cancer ca...
About 2.1 million new diagnosed breast cancer cases among women were estimated for 2018. Triple nega...
Abstract Background The F11R/JAM-A cell adhesion protein was examined as the therapeutic target in t...
<p><b>a</b>, A phage-display random peptide library was used to identify peptides that bind to the b...
To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I...
Background: Claudin-low breast carcinoma represents 19% of all breast cancer cases and is characteri...
Triple-negative breast cancer (TNBC) is an aggressive malignancy characterized by the lack of expres...
Triple-negative breast cancer (TNBC) is the most aggressive and difficult to treat subtype of breast...
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype with poor prognosis and ...
To build a catalog of peptides presented by breast cancer cells, we undertook systematic MHC class I...
The recent development in immune checkpoint inhibitors and chimeric antigen receptor (CAR) T-cells i...